D
Dignify Therapeutics
Drug therapies for on-demand bladder and bowel control.
About Dignify Therapeutics
Dignify Therapeutics is a drug development company that focuses on creating new drug therapies for bladder and bowel disorders. The company's primary focus is on patients with spinal cord injuries, multiple sclerosis, and other neurological conditions who have lost voluntary control of these functions.
The company's business model revolves around the research and development of pharmaceutical agents. They aim to create products that can be administered on-demand to provide safe and effective bladder and bowel control. This approach addresses a significant unmet need in the market, as current solutions are often inadequate or have significant side effects. Dignify Therapeutics operates in the pharmaceutical and biotechnology sectors, targeting a niche market of patients with neurological-related bladder and bowel dysfunction. The company generates revenue through a combination of research grants, venture capital funding, and future licensing or commercialization of its developed drugs.
By developing novel therapies, Dignify Therapeutics seeks to improve the quality of life for its target patient population, offering them greater independence and dignity. The company has a portfolio of patents and is actively engaged in the drug development process, from preclinical studies to potential clinical trials.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Raleigh, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging
Series A2 investors entered at this stage
Eshelman Ventures
RA Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dignify Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dignify Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.